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Ben Willem J. Mol11 and Marjolein Kok1
Abstract
Background: Preterm birth is a major cause of neonatal mortality and morbidity. As preventive strategies are
largely ineffective, threatened preterm labor is a frequent problem that affects approximately 10 % of pregnancies.
In recent years, risk assessment in these women has incorporated cervical length measurement and fetal fibronectin
testing, and this has improved the capacity to identify women at increased risk for delivery within 14 days. Despite
these improvements, risk for preterm birth continues to be increased in women who did not deliver after an
episode of threatened preterm labor, as indicated by a preterm birth rate between 30 to 60 % in this group of
women. Currently no effective treatment is available. Studies on maintenance tocolysis and progesterone have
shown ambiguous results. The pessary has not been evaluated in women with threatened preterm labor, however
studies in asymptomatic women with a short cervix show reduced rates of preterm birth rates as well as perinatal
complications.
The APOSTEL VI trial aims to assess the effectiveness of a cervical pessary in women who did not deliver within
48 h after an episode of threatened preterm labor.
Methods/Design: This is a nationwide multicenter open-label randomized clinical trial. Women with a singleton or
twin gestation with intact membranes, who were admitted for threatened preterm labor, at a gestational age
between 24 and 34 weeks, a cervical length between 15 and 30 mm and a positive fibronectin test or a cervical
length below 15 mm, who did not deliver after 48 h will be eligible for inclusion. Women will be allocated to a
pessary or no intervention (usual care). Primary outcome is preterm delivery < 37 weeks. Secondary outcomes are
amongst others a composite of perinatal morbidity and mortality. Sample size is based on an expected 50 %
reduction of preterm birth before 37 weeks (two-sided test, α 0.05 and β 0.2). Two hundred women with a
singleton pregnancy need to be randomized. Analysis will be done by intention to treat.
(Continued on next page)
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Discussion: The APOSTEL VI trial will provide evidence whether a pessary is effective in preventing preterm birth in
women who did not deliver 48 h after admission for threatened preterm labor and who remain at high risk for preterm
birth.
Trial registration: Trial is registered at the Dutch Trial Register: http://www.trialregister.nl, NTR4210, date of registration:
October 16th 2013.
Keywords: Threatened preterm birth, Treatment, Pessary, Cervical length, Fetal fibronectin
Background
Preterm birth, defined as birth before 37 weeks gestational
age, affects 5-12 % of pregnancies in the developed world
[1, 2]. Since neonatal mortality and severe morbidity rates
are inversely proportional with gestational age, preterm
birth is held accountable for 75 % of neonatal mortality and
70 % of short and long-term neonatal morbidity [1, 2]. Des-
pite all efforts to reduce the incidence of spontaneous pre-
term birth, rates remain constant making preterm birth a
major challenge for obstetric healthcare professionals.
Threatened preterm labor often precedes preterm birth
and is a heterogeneous clinical condition in which labor
seems to start before 37 weeks gestational age [3]. It pre-
sents itself by frequent uterine contractions leading to
cervical changes or by preterm prelabor rupture of the
membranes (PPROM). Approximately 10 % of all preg-
nant women experience an episode of threatened preterm
labor requiring hospital admission [4]. Cervical length and
fetal fibronectin (fFN) testing are used to differentiate
between women at an increased risk for preterm delivery
and those who are unlikely to deliver [5, 6]. The
APOSTEL-I study showed that women with a cervical
length less than 15 mm or a cervical length between 15
and 30 mm and a positive fFN test result are at increased
risk for preterm delivery within seven days. In addition,
the risk of preterm birth in women who do not deliver
within the first seven days continues to be increased (30
to 60 %) in the subsequent weeks of pregnancy [4, 5, 7–9].
Currently, women with threatened preterm labor
before 34 weeks gestational age and a high predicted risk
for delivery at short-term, usually defined as delivery
within seven days, are treated with tocolysis and ante-
natal corticosteroids to improve neonatal outcome [10].
No effective treatment has been established yet for
women who did not deliver, although these women still
remain at an increased risk (25 %) to deliver before
34 weeks when cervical length is < 15 mm or cervical
length is ≥15 and < 30 mm with a positive fFN test
result, respectively [11].
The APOSTEL-II trial showed no beneficiary effect of
maintenance tocolysis with nifedipine compared to pla-
cebo on a composite of adverse perinatal outcome [12].
Results on progesterone as maintenance tocolysis are
contradictive. A Cochrane review found no differences
in reduction of preterm birth or neonatal outcomes [13].
Whilst another recently published systematic review, in-
cluding other studies, did find a significant benefit from
vaginal progesterone in reduction of preterm birth and
prolongation of pregnancy [14]. However, both system-
atic reviews did not include the largest study available
on vaginal progesterone in women with preterm labor
that concluded that there was no beneficiary effect [15].
Currently no RCTs have been published investigating a
cervical pessary in women with threatened preterm
labor. However, results in asymptomatic women with
short cervical length and singleton as well as multiple
pregnancies look promising, with reported reduction of
poor perinatal outcome for singleton (RR 0.14 (95 % CI;
0.01 to 0.39)) and multiple pregnancies (RR 0.23 (95 %
CI; 0.09 to 0.60)) [16, 17]. Additionally, in these women
with a short cervical length decreased rates were found
for delivery < 34 weeks in singleton pregnancies (RR 0.18
(95 % CI; 0.08 to 0.37)) and delivery < 32 weeks in mul-
tiple pregnancies (RR 0.44 (95 % CI 0.20 to 0.98)).
In conclusion, women who do not deliver after an epi-
sode of threatened preterm labor remain at increased
risk of preterm birth in the subsequent weeks of preg-
nancy [11] and as of yet there is no effective treatment
to prevent a preterm delivery in these women Therefore
the objective of the APOSTEL VI trial is to investigate
whether treatment with a cervical pessary is effective in
reducing preterm birth in women who remain at high
risk for preterm birth after an episode of threatened pre-
term labor, in which they did not deliver.
Methods/Design
Aim
The aim of the APOSTEL VI trial is to evaluate whether
treatment with a cervical pessary is effective in reducing
preterm birth < 37 weeks in women who have not deliv-
ered after an episode of threatened preterm labor
between 24+0 and 34+6 weeks gestational age but remain
at increased risk for preterm delivery.
Participants/eligibility criteria
A woman, ≥ 18 years, becomes eligible 48 h after
primary admission for threatened preterm labor and
subsequent inclusion and randomization must take place
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within the following 72 h. Within the first 48 h of admis-
sion treatment with antenatal corticosteroids and tocoly-
sis will be applied according to the national preterm
labor guideline by the Dutch College of Obstetricians
and Gynaecologists (NVOG) [10].
Women who did not deliver after a 48-h episode of
threatened preterm labor will be eligible for randomization
if they comply with the following criteria:
Inclusion criteria
o Threatened preterm labor as defined from;
o Cervical length less than 15 mm (<15 mm)
OR
o Cervical length between 15 and 30 mm (≥15 mm
and < 30 mm) AND a positive fibronectin test result
o No delivery within 48 h after admission for
threatened preterm labor
o Singleton or twin gestation




o Signs of intra-uterine infection (maternal fever,
tachycardia at Cardiotocography (CTG))
o Signs of fetal distress at CTG
o Known major fetal anomalies
o Cervical dilatation ≥3 cm
o >72 h elapsed after becoming eligible to participate
o Residual cervical length that makes it impossible to
place a pessary
A flow diagram for patient selection can be found
in Fig. 1.
Procedures, recruitment, randomization and collection of
data
This is a nationwide multicenter open-label randomized
clinical trial in eight perinatal centers with neonatal
intensive care unit (NICU) facilities in The Netherlands
who collaborate in the Dutch Consortium for Healthcare
Evaluation and Research in Obstetrics and Gynecology -
NVOG Consortium 2.0 (www.studies-obsgyn.nl). The
Dutch Obstetric Consortium is a research collaboration of
obstetric clinics in the Netherlands. All centers will be re-
sponsible for identification, recruitment and randomization
of eligible women.
All women admitted for threatened preterm labor will
receive written study information, available in Dutch
and English and will be counselled by Good Clinical
Practice trained nurses, midwives or doctors. After writ-
ten informed consent, eligible women will be random-
ized to treatment with a cervical pessary or no treatment
(usual care) through a web based application hosted by
the Clinical Trials Unit of the Academic Medical
Center, Amsterdam, according to a computer-generated
randomization sequence in a 1:1 ratio, with a random
block size with a maximum of four. Randomization will
be stratified by type of gestation (singleton versus twin
pregnancy). Demographical, medical and obstetrical
information will be collected at baseline. Baseline infor-
mation will be merged with relevant information
collected during participation in the study in an online
case report form (CRF) by GCP trained research nurses
and midwives.
Intervention
Women allocated to a cervical pessary will receive an
Arabin® pessary. This is a double ring shaped pessary
made of non-allergic, soft and flexible silicone, available
in different sizes. During a simple vaginal examination
that is not painful, a midwife or gynaecologist will assess
which size pessary fits best and subsequently the pessary
is folded and placed around the cervix.
The pessary will remain in place until 36 weeks gesta-
tional age or until delivery, whatever comes first. Removal
of the pessary, reason of removal and reinsertion of a new
pessary will be recorded. Apart from pessary placement,
all women will receive care according to local protocol.
Outcome measures
Primary outcome measure
The primary outcome will be preterm birth before
37 weeks of gestational age.
Secondary outcome measures
Secondary outcomes will be a composite of adverse peri-
natal outcome, time–to-delivery, gestational age at deliv-
ery, preterm birth before 32 and 34 weeks gestational
age, birth weight and percentile, days of admission in
hospital, NICU admission, maternal morbidity, mater-
nal admission days for preterm labor, re-admittance for
new symptoms of preterm labor, side-effects of pessary,
days on additional oxygen or supported ventilation and
costs. Outcomes will be recorded up until 12 weeks
corrected age.
Composite adverse perinatal outcome is defined as
perinatal death or severe morbidity. This composite
includes: severe respiratory distress syndrome (RDS),
bronchopulmonary dysplasia (BPD) according to Jobe
and Bancalari [18], intraventricular haemorrhage
grade III or IV according de Vries et al. and Ment et
al. [19, 20], necrotizing enterocolitis (NEC) > stage 1
according to Bell et al. [21], periventricular
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leucomalacia > grade 1, culture proven sepsis and death
before discharge from the hospital.
Statistical issues
Sample size
Based on findings of previous studies we anticipate a
reduction of preterm birth < 37 weeks with 50 % [16, 17]..
We need to include 180 women in total (two groups of 90
women), with an alpha error of .05 and beta error .2 to
show a reduction of preterm birth < 37 weeks from 40 %
to 20 %. Assuming a 10 % drop out rate we will need to
randomize a total of 200 participants (100 participants per
group). Primarily the aim is to include 200 women with a
singleton pregnancy. Women with a twin pregnancy will
be included as well, however they will not contribute to
the number of required inclusions.
Data analysis
The analysis will be done by intention to treat. The primary
analysis will be limited to singletons only; a secondary
analysis will include both women with a singleton and a
twin pregnancy. Differences in the main outcome preterm
birth < 37 weeks’ between the pessary and no treatment
group will be assessed using a random intercept, fixed
effects binomial regression model with a log-link function,
resulting in a relative risk (RR) with accompanying 95 %
confidence interval (CI). In the secondary analysis stratified
randomization by type of gestation will be accounted for
by adding the type of pregnancy as a covariate to the
regression model. In case of equivalence in outcomes
between treatment allocations, the analysis will be repeated
on a per protocol basis.
Secondary outcomes on the child level in the primary
analysis and secondary outcomes on the maternal level
Fig. 1 Flowchart Apostel VI
Hermans et al. BMC Pregnancy and Childbirth  (2016) 16:154 Page 4 of 6
in both the primary and secondary analysis will be ana-
lyzed equivalent to the primary outcome measure. In the
secondary analysis dichotomous outcomes on the infant
level will be assessed using a binomial generalized esti-
mating equations model (GEEs) with a log-link function
and using an unstructured correlation matrix, resulting
in a relative risk (RR) with accompanying 95 % confi-
dence interval (CI). We will account for interdependence
between outcomes in twin pregnancies by considering
the mother as a cluster variable [22]. Time to delivery
will be assessed using Kaplan-Meier analysis with a log-
rank test to assess the statistical significance between
curves, and a Cox proportional hazards model.
Pre-specified subgroup analysis will be performed on
singletons only and is planned based on risk stratification
(cervical length < 15 mm versus cervical length ≥15 mm
and < 30 mm and positive fetal fibronectin) and obstetric
history subdivided on parity and a history of preterm birth
(nulliparous versus multiparous with history of preterm
birth and multiparous women without a history of pre-
term birth). Subgroup effects will be investigated for the
outcomes preterm birth < 37 weeks and adverse perinatal
outcome and will be assessed by including an interaction
term between the subgrouping variable and treatment
allocation as a covariate to the regression model. When
the interaction shows to be statistically significant (p <
0.05) a stratified subgroup analysis will be performed to
study the effect of treatment in different strata of the
subgroup.
Interim analysis
An independent Data Safety Monitoring Committee
(DSMC) with four members will be formed. Interim ana-
lysis will be performed for safety and efficacy after complete
data collection of the first 100 women [t = 0.5]. The Peto-
stopping rule will be used for testing for efficacy. Given the
strong association between gestational age at birth and
adverse perinatal outcome there is an opportunity to
expand the number of inclusions, if at interim the incidence
of the primary outcome turns out to be clinically relevant
lower in the pessary group. This is in order to obtain suffi-
cient power to detect a difference in adverse perinatal
outcome at the end of the study. Sufficient funds must be
available to expand to number of inclusions.
An independent statistician will perform interim ana-
lysis and an independent DSMC will advise whether the
trial should be stopped or continued.
The data safety monitoring board will be blinded for
the treatment allocation, but can be unblinded by open-
ing a sealed envelope. Adverse Events (AEs) and Serious
Adverse Events (SAEs) will be reported to the DSMC. If
the DSMC feels participating in the trial leads to safety
risks, the DSMC can always advice to stop the trial.
Discussion
Preterm birth is the major cause of neonatal morbidity and
mortality. Of all perinatal mortality, 50 % to 70 % is associ-
ated with preterm birth. Similarly, neonatal morbidity is
inversely proportional to gestational age and thus preterm
birth. Since women who do not deliver after an episode of
threatened preterm labor remain at an increased risk of
preterm birth and currently no effective intervention is
available, it is important to evaluate potential treatments
for effectiveness. As such, the pessary seems a potential
alternative in this group of women.
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